Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation: a prospective multicentre cohort study by Violi, Francesco et al.
Relationship between low Ankle-
Brachial Index and rapid renal function
decline in patients with atrial
fibrillation: a prospective multicentre
cohort study
Francesco Violi,1 Daniele Pastori,1 Francesco Perticone,2 William R Hiatt,3
Angela Sciacqua,2 Stefania Basili,1 Marco Proietti,1 Gino R Corazza,4
Gregory Y H Lip,5 Pasquale Pignatelli,1 in collaboration with the ARAPACIS
(Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-
Collaborative Italian Study) STUDY group
To cite: Violi F, Pastori D,
Perticone F, et al.
Relationship between low
Ankle-Brachial Index and
rapid renal function decline in
patients with atrial fibrillation:
a prospective multicentre
cohort study. BMJ Open
2015;5:e008026.
doi:10.1136/bmjopen-2015-
008026
▸ Prepublication history
and additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2015-
008026).
Received 21 February 2015
Revised 23 April 2015
Accepted 26 April 2015
For numbered affiliations see
end of article.
Correspondence to
Professor Francesco Violi;
francesco.violi@uniroma1.it
ABSTRACT
Objective: To investigate the relationship between
Ankle-Brachial Index (ABI) and renal function
progression in patients with atrial fibrillation (AF).
Design: Observational prospective multicentre cohort
study.
Setting: Atherothrombosis Center of I Clinica Medica
of ‘Sapienza’ University of Rome; Department of
Medical and Surgical Sciences of University Magna
Græcia of Catanzaro; Atrial Fibrillation Registry for
Ankle-Brachial Index Prevalence Assessment-
Collaborative Italian Study.
Participants: 897 AF patients on treatment with
vitamin K antagonists.
Main outcome measures: The relationship between
basal ABI and renal function progression, assessed by
the estimated Glomerular Filtration Rate (eGFR)
calculated with the CKD-EPI formula at baseline and
after 2 years of follow-up. The rapid decline in eGFR,
defined as a decline in eGFR >5 mL/min/1.73 m2/year,
and incident eGFR<60 mL/min/1.73 m2 were primary
and secondary end points, respectively.
Results: Mean age was 71.8±9.0 years and 41.8%
were women. Low ABI (ie, ≤0.90) was present in 194
(21.6%) patients. Baseline median eGFR was 72.7 mL/
min/1.73 m2, and 28.7% patients had an eGFR<60 mL/
min/1.73 m2. Annual decline of eGFR was −2.0 (IQR
−7.4/−0.4) mL/min/1.73 m2/year, and 32.4% patients
had a rapid decline in eGFR. Multivariable logistic
regression analysis showed that ABI ≤0.90 (OR 1.516
(95% CI 1.075 to 2.139), p=0.018) and arterial
hypertension (OR 1.830 95% CI 1.113 to 3.009,
p=0.017) predicted a rapid eGFR decline, with an
inverse association for angiotensin converting enzyme
(ACE) inhibitors/angiotensin receptor blockers (OR
0.662 95% CI 0.464 to 0.944, p=0.023). Among the
639 patients with AF with eGFR >60 mL/min/1.73 m2,
153 (23.9%) had a reduction of the eGFR <60 mL/min/
1.73 m2. ABI ≤0.90 was also an independent predictor
for incident eGFR<60 mL/min/1.73 m2 (HR 1.851, 95%
CI 1.205 to 2.845, p=0.005).
Conclusions: In patients with AF, an ABI ≤0.90 is
independently associated with a rapid decline in renal
function and incident eGFR<60 mL/min/1.73 m2. ABI
measurement may help identify patients with AF at risk
of renal function deterioration.
Trial registration number: NCT01161251.
INTRODUCTION
Atrial fibrillation (AF) is the most common
arrhythmia encountered in daily clinical
practice, accounting for approximately
one-third of all hospitalisations for a cardiac
rhythm abnormality. It is associated with a
Strengths and limitations of this study
▪ Measurement of Ankle-Brachial Index (ABI) is a
simple, inexpensive and standardised method to
explore systemic atherosclerosis.
▪ Renal function assessment and deterioration
were assessed using international definitions.
▪ ABI measurement may help identify patients with
atrial fibrillation (AF) who are at high risk of renal
function deterioration, and eventually require
serum creatinine monitoring.
▪ Our findings may turn particularly useful in the
era of non-vitamin K antagonist oral anticoagu-
lants, whose dosage requires to be tailored in AF
patients with renal impairment.
▪ Our analysis was performed only in a Caucasian
population from the same country (Italy), limiting
the generalisability of the findings.
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fivefold increase in the risk for stroke, and is estimated
to be the cause of almost 15% of all strokes.1
Chronic kidney disease (CKD) is a frequent feature of
patients with AF having an important impact on clinical
outcomes, as it predisposes to both ischaemic stroke and
bleeding.2–4 Diagnosis and evaluation of CKD progres-
sion is a part of comprehensive AF management, not
only to prevent adverse clinical events, but also to aid
decision-making on oral anticoagulation. In fact, evalu-
ation of renal function is a key aspect when prescribing
of non-vitamin K antagonist oral anticoagulants
(NOACs), especially dabigatran.5
Ankle-Brachial Index (ABI) is a simple, inexpensive
and non-invasive marker of peripheral artery disease and
systemic atherosclerosis, which is associated with an
increased risk of cardiovascular events.6 7 Prior studies
have reported that a low ABI (ie, ≤0.90) is present in
patients with CKD and predicts a rapid decline in renal
function in the general population.8 We have recently
reported that low ABI can be detected in about 20% of
the AF population,9 suggesting that systemic atheroscler-
osis is a frequent feature in this setting.10 No prior studies
have reported on the relationship between low ABI and
rapid decline in renal function in patients with AF.
We hypothesised that low ABI may predict a rapid
decline in renal function and may represent a useful,
rapid and simple clinical tool to risk-stratify those
patients at risk of renal impairment. Thus, we analysed
the relationship between low ABI and the occurrence of
rapid renal function decline, and incident CKD as
assessed by renal function <60 mL/min/1.73 m2 during
a follow-up of approximately 2 years in a large popula-
tion affected by AF.
METHODS
This was an observational prospective multicentre study
including patients with AF recruited from the
Atherothrombosis Center of I Clinica Medica of ‘Sapienza’
University of Rome, from the Department of Medical and
Surgical Sciences, University Magna Græcia of Catanzaro,
Italy, and from those included in the cohort of the Atrial
Fibrillation Registry for Ankle-Brachial Index Prevalence
Assessment-Collaborative Italian Study (see online supple-
mentary appendix) who had a double determination of
serum creatinine.
All patients with non-valvular AF aged >18 years and
with a follow-up of at least 1 year were included in this
prospective study. Exclusion criteria were the presence
of valvular diseases (prosthetic heart valves or any severe
valvulopathy), chronic infectious diseases (ie, HIV infec-
tion, hepatitis C virus, hepatitis B virus) or autoimmune
systemic disease. Subjects were also excluded from the
study if they had active cancer or liver insufficiency
(eg, cirrhosis). At baseline, anthropometric data as well
as comorbidities and concomitant therapies were col-
lected. The presence of cardiovascular risk factors were
defined as previously described.11
At baseline, serum creatinine (mg/dL) was obtained for
all patients. Estimated glomerular filtration rate (eGFR)
was calculated using the CKD-EPI formula.12 Patients were
classified in eGFR categories according to Kidney Disease:
Improving Global Outcomes (KDIGO) guidelines:13
normal eGFR (>90 mL/min/1.73 m2, Stage G1), mildly
decreased eGFR (89–60 mL/min/1.73 m2, Stage G2),
moderately decreased eGFR (59–30 mL/min/1.73 m2,
Stage G3) and severely decreased eGFR (<30 mL/min/
1.73 m2, Stage G4). A second serum creatinine was col-
lected during follow-up. The primary end point of the
study was to evaluate the rapid decline in eGFR defined as
a loss in glomerular filtration >5 mL/min/1.73 m2/year.13
The secondary end point of the study was incident CKD as
defined as an eGFR<60 mL/min/1.73 m2.
ABI measurement
At baseline, trained clinical staff measured the ABI in all
patients using an 8 MHz CW Vascular Doppler
(Risingmed Model:RFD-B). ABI was calculated as the
ratio of systolic blood pressure obtained from the ankle
and brachial arteries. Ankle and brachial systolic blood
pressures were measured separately for the right and left
sides, and ABI was assessed separately for the right and
left legs using the highest arm pressure as the denomin-
ator. Patients were categorised into 2 groups according
to their ABI value: (1) normal, if both left and right ABI
values were normal (ABI >0.90) and (2) low, if at least
one of the two values of ABI was ≤0.90.
The local ethical boards approved the protocol study.
The study was conducted according to the principles
embodied in the Declaration of Helsinki, and all
patients included in the present study provided written
informed consent at enrolment.
Statistical analyses
Categorical variables are reported as counts (percent-
age). Continuous variables are expressed as mean±SD or
median and interquartile range (IQR) (IQR; 25th–75th
percentile), as appropriate. Two-sided t tests or the
Wilcoxon rank sum test, depending on the shape of the
distribution curve, was used to compare means. Pearson
χ2 test was used to compare proportions. Bivariate ana-
lysis was performed with Pearson’s linear correlation.
Appropriate non-parametric tests (Mann-Whitney U test
and Spearman rank correlation test) were employed for
all the other variables.
We calculated the annual absolute decline in eGFR,
expressed as the difference between the two eGFR values
(follow-up eGFR—basal eGFR/years of follow-up).
We divided the population according to the presence or
absence of a rapid decline in eGFR (>5 mL/min/
1.73 m2/year), to analyse clinical characteristics of patients
with renal function deterioration. We performed a multi-
variable logistic regression analysis to calculate the
adjusted ORs of factors associated with the annual rapid
decline in kidney function.
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The multivariate analysis was determined including all
variables that could potentially affect renal function. In
particular, we included as covariates the following vari-
ables: age, gender, ABI≤0.90, type of AF (persistent/per-
manent vs paroxysmal AF), presence of arterial
hypertension, diabetes, heart failure, history of ischae-
mic stroke/transient ischaemic attack (TIA), history of
myocardial infarction/cardiac revascularisation, as well
as the use of angiotensin converting enzyme (ACE) inhi-
bitors/angiotensin receptor blockers (ARBs), β blockers,
calcium channel antagonists, statins, antiplatelet therapy
and body mass index.
We also analysed the clinical characteristics of
patients with AF developing incident eGFR<60 mL/
min/1.73 m2. Considering that the second creatinine
was not collected at the same time during follow-up
for all patients with AF, we used a Cox proportional
hazard regression analysis to calculate the relative
adjusted hazard ratios (HRs) of factors associated with
incident eGFR<60 mL/min/1.73 m2, using the same
variables listed above with the addition of baseline
eGFR, which has been shown to be predictive of inci-
dent eGFR<60 mL/min/1.73 m2.14
All tests were two-tailed and analyses were performed
using computer software packages (SPSS-V.18.0, SPSS).
Only p values <0.05 were considered as statistically
significant.
RESULTS
Clinical characteristics of 897 patients with AF included
in the study are described in table 1. Mean age was 71.8
±9.0 years, and 41.8% were women. The median
CHA2DS2-VASc score was 3.0 (2.0–4.0).
In the whole population, the baseline median eGFR
was 72.7 mL/min/1.73 m2 (56.8–88.8), and 258 (28.7%)
had an eGFR<60 mL/min/1.73 m2. Distribution of
classes of eGFR in the whole cohort is reported in figure
1A. Prevalence of normal, mild, moderate and severe
eGFR was 23.1%, 48.2%, 26.1% and 2.7%, respectively.
Using 60 mL/min/1.73 m2 as a cut-off to define the
CKD, we found that patients with renal disease were
older, more frequently women, with a clinical history
more complicated by heart failure and myocardial
infarction/coronary heart disease and with a higher
CHA2DS2-VASc score (table 1). Moreover, a higher
prevalence of permanent AF was found in patients with
baseline eGFR<60 mL/min/1.73 m2 (table 1).
In the whole cohort, 194 (21.6%) had a value of ABI
≤0.90. No significant differences of low ABI were found
between paroxysmal/persistent and permanent AF (19.6
vs 24.3%, p=0.102). The prevalence of reduced eGFR
(<60 mL/min/1.73 m2) was significantly higher in
patients with ABI ≤0.90 compared with those with ABI
>0.90 (45.4 vs 24.2%, p<0.001) (figure 1B). Thus,
patients with ABI ≤0.90 had a median eGFR of 65.0
(46.9–82.4) vs 74.1 (60.1–90.1) mL/min/1.73 m2 in
those with normal ABI (p<0.001).
A second measurement of serum creatinine was
obtained for all patients after a median of 2.0 (1.0–
3.4) years. During follow-up, median eGFR decreased sig-
nificantly from a baseline of 72.7 to 63.6 (48.8–82.0) mL/
min/1.73 m2 (p<0.001) with a parallel increase in the
prevalence of impaired renal function (figure 1A).
Overall, the annual median decline in eGFR was −2.0
(IQR −7.4/−0.4) mL/min/1.73 m2/year, with no differ-
ences between paroxysmal/persistent and permanent AF
(−2.1 (−7.5/−0.45) vs −2.0 (−7.1/−0.30), p=0.453).
Table 1 Baseline characteristics of entire cohort, according to the presence or absence of renal impairment (eGFR<60 mL/min)
Overall
Baseline eGFR
<60 mL/min/1.73 m2
p Value(n=897) No (n=639) Yes (n=258)
Age (years) 71.8±9.0 69.8±8.9 76.7±7.3 <0.001
Women (%) 41.8 36.9 53.9 <0.001
Permanent AF (%) 43.1 40.7 49.2 0.021
Body mass index (kg/m2) 27.9±4.6 28.1±4.6 27.7±4.5 0.300
Ankle-Brachial Index ≤0.90 (%) 21.6 16.6 34.1 <0.001
CHA2DS2-VASc score 3.0 (2.0–4.0) 3.0 (2.0–4.0) 4.0 (3.0–5.0) <0.001
Arterial hypertension (%) 86.3 85.4 88.4 0.284
Diabetes mellitus (%) 24.1 22.7 27.5 0.075
History of MI/CHD (%) 18.4 16.7 22.5 0.029
Heart failure (%) 19.0 16.4 25.2 0.003
History of stroke/TIA (%) 11.3 11.1 11.6 0.816
ACE inhibitor/ARBs (%) 72.8 71.4 76.4 0.074
β blockers (%) 48.6 47.1 52.3 0.090
Calcium channel antagonists (%) 27.2 26.0 30.2 0.195
Statins (%) 44.4 43.3 46.9 0.336
Antiplatelets (%) 19.6 20.5 17.4 0.309
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARBs, angiotensin receptor blockers; CHD, coronary heart disease; eGFR,
estimated glomerular filtration rate; MI, myocardial infarction; TIA, transient ischaemic attack.
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Patients with AF with ABI ≤0.90 showed a significantly
higher deterioration of renal function compared with
those with normal ABI (−3.2 (−8.3 to −0.5) vs −1.9
(−6.8 to −0.4) mL/min/1.73 m2, p=0.020).
Rapid decline in renal function
Analysis of rapid deterioration in renal function showed
that 291 (32.4%) patients with AF had a rapid decline in
eGFR. The clinical characteristics of these patients are
reported in table 2.
The rapid decline in renal function was detected in
97 (33.3%) patients with AF and normal eGFR at
baseline, 148 (50.9%) with mildly decreased eGFR,
44 (15.1%) with moderately decreased eGFR and in 2
(0.7%) patients with baseline eGFR severely decreased.
A multivariable logistic regression analysis (table 3)
showed that factors independently predicting rapid
Figure 1 (A) Distribution of classes of estimated glomerular filtration rate (eGFR) in the whole cohort of patients with atrial
fibrillation (AF) at baseline and during follow-up. (B) Prevalence of Ankle-Brachial Index (ABI) >0.90 (Row: 0) ABI ≤0.90 (Row: 1)
in patients with eGFR ≥60 mL/min/1.73 m2 (Red columns) or <60 mL/min/1.73 m2 (Blue columns).
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eGFR decline were ABI ≤0.90 (OR 1.516 (1.075 to
2.139), p=0.018) and arterial hypertension (OR 1.830
(1.113 to 3.009), p=0.017), while the use of ACE inhibi-
tors/ARBs showed a protective effect (OR 0.662 (0.464
to 0.944), p=0.023).
Incident eGFR<60 mL/min/1.73 m2
At baseline, 639 (71.2%) patients with AF had an eGFR
>60 mL/min/1.73 m2; during the follow-up, 153
(23.9%) patients with an eGFR >60 mL/min/1.73 m2
had an eGFR<60 mL/min/1.73 m2. As shown in table 4,
patients with AF with incident eGFR<60 mL/min/
1.73 m2 were older, more frequently women, and
affected by arterial hypertension compared with those
with stable renal function. Low ABI was more frequent
in patients with AF with incident eGFR<60 mL/min/
1.73 m2 (table 4).
A Cox regression analysis found a positive association
of ABI ≤0.90 and age with incident eGFR<60 mL/min/
1.73 m2, while baseline eGFR and the use of calcium
channel antagonists were inversely associated (table 5).
DISCUSSION
This report shows that low ABI (ie ≤0.90) is associated
with rapid deterioration of renal function and with an
increased risk of incident kidney disease in a population
affected by AF. The baseline analysis of our population
showed that renal impairment was common in the AF
population, as only 23% of patients have a normal renal
function (eGFR >90 mL/min), while moderate renal
impairment (eGFR<60 mL/min) was detected in
approximately 30% of patients. Similar findings were
seen by Roldan et al,3 who found 28% with moderate
renal impairment in 978 patients affected by AF.3
Furthermore, patients with AF had an annual decline in
Table 2 Clinical characteristics of patients with a rapid
decline in renal function (>5 mL/min/1.73 m2/year)
Rapid
decline
in eGFR
(n=291)
No
decline
in eGFR
(n=606) p Value
Age (years) 72.1±8.4 71.6±9.3 0.486
Body mass index (kg/m2) 27.5±4.5 28.2±4.6 0.039
Women (%) 41.9 41.7 0.960
Permanent AF (%) 42.3 43.6 0.720
Ankle-Brachial Index
≤0.90 (%)
26.5 19.3 0.015
Arterial hypertension (%) 88.7 85.1 0.152
Diabetes (%) 23.0 24.6 0.608
Heart failure (%) 19.6 18.6 0.736
History of stroke/TIA (%) 10.0 11.9 0.396
History of MI/CHD (%) 19.6 17.8 0.523
Antiplatelet (%) 18.2 20.3 0.462
ACE inhibitors/ARBs (%) 69.4 74.4 0.068
β blockers (%) 51.5 47.2 0.222
Calcium channel
antagonists (%)
27.8 26.9 0.768
Statins (%) 43.6 44.7 0.761
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARBs,
angiotensin receptor blockers; CHD, coronary heart disease;
eGFR, estimated glomerular filtration rate; MI, myocardial
infarction; TIA, transient ischaemic attack.
Table 3 Multivariable-adjusted ORs of factors associated
with a rapid decline in kidney function (eGFR decrease
>5 mL/min/1.73 m2/year)
p Value OR 95% CI
Age (years) 0.988 0.998 0.741 to 1.344
Women (%) 0.819 0.998 0.981 to 1.015
Body mass index (kg/m2) 0.080 0.955 0.938 to 1.004
Persistent/permanent
AF (%)
0.573 0.919 0.687 to 1.231
Ankle-Brachial Index
≤0.90 (%)
0.018 1.516 1.075 to 2.139
Arterial hypertension (%) 0.017 1.830 1.113 to 3.009
Diabetes (%) 0.485 0.883 0.622 to 1.253
Heart failure (%) 0.969 0.993 0.683 to 1.443
History of stroke/TIA (%) 0.176 0.723 0.452 to 1.156
History of MI/CHD (%) 0.800 1.052 0.708 to 1.564
ACE inhibitors/ARBs (%) 0.023 0.662 0.464 to 0.944
β blockers (%) 0.215 1.206 0.897 to 1.621
Calcium channel
antagonists (%)
0.673 1.074 0.771 to 1.497
Statins (%) 0.848 0.971 0.720 to 1.311
Antiplatelet (%) 0.464 0.870 0.600 to 1.262
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARBs,
angiotensin receptor blockers; CHD, coronary heart disease;
eGFR, estimated glomerular filtration rate; MI, myocardial
infarction; TIA, transient ischaemic attack.
Table 4 Characteristics of patients developing incident
eGFR<60 mL/min/1.73 m2
Incident eGFR<60 mL/min/
1.73 m2
Yes
(n=153)
No
(n=486) p Value
Age (years) 73.2±8.2 68.7±8.8 <0.001
Body mass index (kg/m2) 27.5±4.5 28.2±4.7 0.090
Women (%) 45.1 34.4 0.016
Permanent AF (%) 39.2 41.2 0.760
Ankle-Brachial Index
≤0.90 (%)
23.5 14.4 0.008
Arterial hypertension (%) 90.8 83.7 0.030
Diabetes (%) 18.3 24.1 0.137
Heart failure (%) 12.4 17.7 0.124
History of stroke/TIA (%) 11.1 11.1 1.000
History of MI/CHD (%) 17.0 16.7 0.925
Antiplatelet (%) 16.3 21.8 0.087
ACE inhibitors/ARBs (%) 72.5 71.0 0.759
β blockers (%) 49.0 46.5 0.586
Calcium channel
antagonists (%)
28.1 25.3 0.492
Statins (%) 44.4 43.0 0.754
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARBs,
angiotensin receptor blockers; CHD, coronary heart disease;
eGFR, estimated glomerular filtration rate; MI, myocardial
infarction; TIA, transient ischaemic attack.
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renal function of approximately 2–5 mL/min, which is
consistent with previous data in a very old AF
population.15
To the best of our knowledge, only one previous study
analysed the rate and predictors of rapid renal disease
progression in AF. Roldan et al3 demonstrated a progres-
sion of CKD ≥10 mL/min in 21% of patients with AF at
2 years of follow-up, with age, female gender and arterial
hypertension being significantly associated with a
decline in renal function. This study, using the general
definition of rapid decline in renal function >5 mL/min
per year,13 shows a rapid function deterioration in
32.4% of patients with AF. Rapid deterioration was more
evident in patients with AF with normal or mildly
decreased renal function at baseline.
The novelty of this study is in the analysis of the inter-
play between low ABI and the rapid renal function
deterioration in a population affected by AF. Thus far,
only one study has explored this interplay in the general
population, by comparing 51 participants with ABI
≤0.90 vs 2541 with ABI >0.90, and demonstrated that
over a follow-up of 9 years, ABI ≤0.90 independently pre-
dicted a rapid decline in eGFR.8 In our cohort, which
included 194 (21.6%) patients with AF with ABI ≤0.90,
we confirm that ABI ≤0.90, along with hypertension, was
significantly associated with a rapid decline in renal
function, while the use of ACE/ARB inhibitors was
protective.
This would suggest that low ABI, in addition to being
a marker of systemic atherosclerosis, represents a marker
of vascular damage occurring not only in the coronary
or cerebral tree, but also in the circulation of other
organs such as the kidney. Unfortunately, we cannot
determine if the association between low ABI and rapid
decline in renal function is a reflection of atheroscler-
otic burden in the micro-circulation and/or macro-
circulation, but this issue deserves further investigation.
However, our data are in keeping with other methods
exploring atherosclerosis disease, such as pulse wave vel-
ocity, which have been shown to be predictive of renal
function decline in different clinical settings.16 17
Analysis of incident eGFR<60 mL/min/1.73 m2
showed that approximately 24% of AF with baseline
values >60 mL/min/1.73 m2 had renal function impair-
ment. Further support for the role of ABI as a predictor
of renal function deterioration was provided by the sig-
nificant association between low ABI and incident
eGFR<60 mL/min. This is in contrast to Foster et al,8
who found only a trend between low ABI and incident
CKD, but their small sample size may perhaps account
for the different findings.
This study has implications and limitations. Patients
with AF have a relatively high prevalence and incidence
of renal impairment which is related to ABI, a marker of
systemic atherosclerosis. This finding may turn useful
particularly in the era of NOACs which are excreted,
even if to a different degree by the kidney, and whose
dosage requires to be tailored in case of patients with AF
with moderate renal function.18
In this context, ABI measurement could be particu-
larly useful in identifying patients who are at high risk of
renal function deterioration, and will eventually require
serum creatinine monitoring.
Furthermore, identification of patients at high risk of
renal disease progression may be of use to identify
patients who are at higher risk of cardiovascular events.
Our analysis performed only in a Caucasian population is
a study limitation, as it cannot be translated to other race
or ethnic groups. Another limitation of the study is repre-
sented by the lack of data on proteinuria or haematuria,
which can be associated with an abnormality in the
urinary tract even with a preserved eGFR (>90 mL/min)
and with ABI<0.9.19 Finally, in our study, a decline in
renal function has been assessed using only a second
value of serum creatinine during follow-up; the analysis
of renal function progression would be more appropriate
by assessing more than two values of creatinine.
In conclusion, the study provides evidence that in
patients with AF, an ABI ≤0.90 is independently asso-
ciated with a rapid decline in renal function. ABI meas-
urement may help identify patients with AF at risk of
renal function deterioration.
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Table 5 Adjusted HRs, based on a Cox proportional
hazards analysis of factors associated with incident
eGFR<60 mL/min/1.73 m2
p Value HR 95% CI
Age (years) 0.019 1.030 1.005 1.056
Baseline eGFR
(mL/min/1.73 m2)
<0.001 0.957 0.944 0.971
Body mass index (kg/m2) 0.777 1.006 0.967 1.045
Women (%) 0.994 1.001 0.711 1.409
Permanent AF (%) 0.395 0.862 0.611 1.214
Ankle-Brachial Index
≤0.90 (%)
0.005 1.851 1.205 2.845
Arterial hypertension (%) 0.052 1.860 0.994 3.481
Diabetes (%) 0.151 0.713 0.449 1.132
Heart failure (%) 0.841 1.055 0.627 1.774
History of stroke/TIA (%) 0.867 1.046 0.619 1.767
History of MI/CHD (%) 0.172 0.725 0.457 1.150
Antiplatelet (%) 0.518 0.864 0.555 1.346
ACE inhibitors/ARBs (%) 0.442 0.842 0.543 1.306
β blockers (%) 0.788 1.052 0.728 1.521
Calcium channel
antagonists (%)
0.029 0.640 0.429 0.954
Statins (%) 0.434 1.148 0.812 1.622
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARBs,
angiotensin receptor blockers; CHD, coronary heart disease;
eGFR, estimated glomerular filtration rate; MI, myocardial
infarction; TIA, transient ischaemic attack.
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Collaborators ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index
Prevalence Assessment-Collaborative Italian Study) study group: see online
supplementary appendix.
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